Evidence map›Paper›PMID 18936966›Full record

ArticleVirchows Archiv : an international journal of pathology2008

Ancillary testing of liquid-based cytology specimens for identification of patients at high risk of cervical cancer.

Takuma Fujii, Miyuki Saito, Takashi Iwata, Nobumaru Hirao, Hiroshi Nishio, Akiko Ohno, Katsumi Tsukazaki, Makio Mukai, Kaori Kameyama, Daisuke Aoki

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Takuma FujiiDepartment of Obstetrics and Gynecology, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. fujiit@sc.itc.keio.ac.jp
Miyuki Saito
Takashi Iwata
Nobumaru Hirao
Hiroshi Nishio
Akiko Ohno
Katsumi Tsukazaki
Makio Mukai
Kaori Kameyama
Daisuke Aoki
Keio University · JPKeio University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integration of human papillomavirus DNAs into the host genome is crucial to the development of cervical cancer. Overexpression of the P16 protein has been reported in cervical intraepithelial neoplasia (CIN) as well as cervical cancer. Such molecular biomarkers have been utilized for ancillary testing of liquid-based cytology specimens; however, their clinical application remains controversial. To detect CIN 2 or more advanced lesions, 153 liquid-based cytology (LBC) specimens were investigated to determine the physical status of the human papillomavirus (HPV) DNA by in situ hybridization (ISH) and to detect overexpression of the P16 protein by immunocytochemistry combined with HPV genotyping by polymerase chain reaction. The combination of ISH, P16 immunocytochemistry, and LBC showed high sensitivity (89.3%) as well as high specificity (92.6%). We confirmed the usefulness of P16 immunocytochemistry combined with ISH and HPV genotyping as ancillary molecular-biological tests of LBC specimens for identifying patients at high risk of cervical cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCervix UteriCyclin-Dependent Kinase Inhibitor p16Cytological TechniquesDNA, ViralFemaleGenotypeHuman papillomavirus 16HumansImmunohistochemistryIn Situ HybridizationMiddle AgedNeoplasm ProteinsBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, ViralNeoplasm Proteins

Identifiers

PMID18936966
OpenAlexW2034185073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.